Knee osteoarthritis (OA) is a musculoskeletal disorder that has high economic and social costs and may have a heavy impact on the patients’ quality of life. In patients aged <60 years, knee OA has a prevalence of about 10% in men and 13% in women. Pharmacological treatments, such as oral or topical administration of non-steroidal anti-inflammatory drugs, are effective only on a short-term basis, and their prolonged use has several adverse effects. OA causes structural, cellular and biochemical changes in the affected joints. Inflammation leads to progressive degradation of the components of the extracellular matrix (ECM), including collagen. Thus, the effect of administration of exogenous collagen has been investigated. A novel collagen formulation (CHondroGrid®, CG) consisting in low molecular weight hydrolyzed bovine collagen for intra- and peri-articular injection has been placed on the market as a medical device.
This retrospective and multicentric study aim to assess CHondroGrid® safety and performance in reducing symptoms in 70 patients suffering from knee osteoarthritis.
Sede Amministrativa e legale
via E. Fermi, 49
36057 Arcugnano, Vicenza (VI) - Italia
Tel. +39 0444 289366
Fax: +39 0444 285272
Centro Polifunzionale di produzione
Via G. Agnelli, 3
10020 Riva presso Chieri, Torino (TO) - Italia